insurance coverage tirzepatide for Tirzepatide: Medical Necessity & Approval – PlexusDx Navigating insurance coverage for GLP-1's

Lombardo P et al

2.4 Quality assessment The methodological quality of the included RCTs was assessed separately by two investigators through the Cochrane collaborations tool for assessing risk of bias, involving the following items: 1) random sequence generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) blinding of outcome assessment, 5) incomplete outcome data, 6) selective reporting, and 7) other bias

You can review the Semaglutide vs Tirzepatide comparison before your consultation

Report persistent side effects, inadequate response, or new symptoms promptly

Whilst treatment failed to reduce amyloid plaque load, liraglutide did prevent the decline in cerebral glucose metabolism after 26 weeks compared to placebo treatment, which suggests that liraglutide may modify disease progression

By week 28, PHQ-9 had settled to 4 and HDRS-17 to 6, with the patient remaining on vortioxetine and bupropion